NT-Z001 / Navega Therapeutics - LARVOL DELTA

Navega Therapeutics Announces CIRM Grant for Treatment of Chronic Pain (PRNewswire) - "Navega Therapeutics...today announced the receipt of a $4M Translational Science grant from CIRM for the relief of neuropathic pain. Founder and CEO, Ana Moreno, expressed her gratitude for the second grant from CIRM which has supported the development of NT-Z001. Navega harnesses its AI-enabled platform for the construction of novel, highly selective epigenetic editors. The expression of Nav1.7 is down-regulated by the epigenetic editor, NT-Z001, and results in relief of chronic pain across multiple animal models. The grant will fund the final preclinical development studies of NT-Z001 leading to an IND."

Financing • Pain